# OnCo record nct06903273 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06903273/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06903273", "NCT06903273" ;
  schema:name "Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma"@en ;
  schema:alternateName "TisGCS for BTC"@en ;
  schema:description "A phase 2 trial of tislelizumab, gemcitabine, cisplatin and S-1 in gallbladder cancer and other biliary tract cancers, run by National Cheng-Kung University Hospital, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06903273/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06903273> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "gallbladder-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/tegafur-gimeracil-oteracil/> .